The latter have been shown to reduce heart failure events and cardiovascular mortality in patients with heart failure and with CKD.36,37 Similarly, novel nonsteroidal mineralocorticoid receptor antagonists, which are known to reduce cardiac fibrosis development, were recently shown to specifically reduce heart failure–related outcomes in patients with CKD and diabetes but do not reduce cardiovascular mortality.38 Thus, future studies have to determine as to whether patients with LOY will particularly benefit from distinct medications in CKD. This evidence concerns the gene NR3C2 and diabetes mellitus.